STRATA Skin Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on March 24, 2021
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced it will release its fourth quarter and full year financial results on March 24, 2021, after market close. Management will hold a conference call at 4:30 p.m. ET to discuss the results and provide a corporate update, which will also be webcasted. STRATA specializes in medical technology, focusing on innovative products for dermatological conditions, including its XTRAC® excimer laser. The company’s DTC advertising strategy has expanded its partner dermatology clinic network to over 832 locations across the U.S.
- Fourth quarter and full year results announcement scheduled for March 24, 2021.
- Established a network of over 832 dermatology partner clinics in the U.S.
- Introduced Home by XTRAC™, providing at-home treatment options.
- None.
HORSHAM, Pa., March 10, 2021 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or the “Company”), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced that it plans to release its fourth quarter and full year financial results after the market closes on Wednesday, March 24, 2021. Management will hold a conference call to review the financial results and provide a corporate update starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call will be concurrently webcast.
The link to the webcast will be available on the STRATA Skin Sciences website at: www.strataskinsciences.com under the investor relations section and will be archived for future reference. To listen to the conference call, please dial 1-877-451-6152 (US/Canada), 1-201-389-0879 (International), or 1 809 406 247 (Israel) and use the conference ID number 13717061.
About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions. Its products include the XTRAC® excimer laser and VTRAC® lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions.
The Company’s proprietary XTRAC® excimer laser delivers a highly targeted therapeutic beam of UVB light to treat psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma, diseases which impact over 31 million patients in the United States alone. The technology is covered by multiple patents, including exclusive rights for patents for the delivery of treatment to vitiligo patients.
STRATA’s unique business model leverages targeted Direct to Consumer (DTC) advertising to generate awareness and utilizes its in-house call center and insurance advocacy teams to increase volume for the Company’s partner dermatology clinics.
The XTRAC business has used this proven DTC model to grow its domestic dermatology partner network to over 832 clinics, with a worldwide installed base of over 2,300 devices. The Company is able to offer
The Company has now introduced its Home by XTRAC™ business, leveraging in-house resources; including DTC advertising, in-house call center and its insurance reimbursement team to provide an at-home, insurance-reimbursed treatment option for patients with certain skin diseases that do not qualify for in-office treatments.
Investor Relations Contact:
Leigh Salvo
(415) 937-5404
ir@strataskin.com
FAQ
When will STRATA Skin Sciences release its fourth quarter financial results?
What time is the STRATA Skin Sciences conference call on March 24, 2021?